Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 8.4% - Here's What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shares traded up 8.4% during trading on Thursday . The stock traded as high as $23.44 and last traded at $23.27. 556,714 shares were traded during trading, an increase of 83% from the average session volume of 304,555 shares. The stock had previously closed at $21.46.

Analysts Set New Price Targets

Several research analysts have commented on the company. Robert W. Baird raised their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. HC Wainwright increased their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Finally, The Goldman Sachs Group started coverage on Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $41.20.

Enliven Therapeutics Price Performance

The stock has a 50-day moving average price of $19.93 and a two-hundred day moving average price of $20.28.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total transaction of $135,606.78. Following the completion of the transaction, the chief operating officer owned 303,309 shares in the company, valued at approximately $6,169,305.06. This trade represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $22.18, for a total value of $277,250.00. Following the transaction, the chief executive officer owned 952,892 shares of the company's stock, valued at $21,135,144.56. The trade was a 1.29% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,111 shares of company stock worth $1,891,776. Insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its holdings in Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after purchasing an additional 508 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after buying an additional 718 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after buying an additional 1,285 shares during the period. Finally, California State Teachers Retirement System boosted its stake in shares of Enliven Therapeutics by 10.2% during the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after buying an additional 1,940 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.